The U.S. federal government spent an estimated $1.8 billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health suggests.
Medicare program spent $1.8 billion in 2019 on drugs without confirmed clinical benefits
May 25, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022